NIH × Has results × Lymphoma, Large-Cell, Anaplastic × Clear all Dose-Adjusted EPOCH Chemotherapy and Rituximab (CD20+) in Previously Untreated Aggressive Non-Hodgkin's Lymphoma
Phase 2 Completed
348 enrolled 15 charts
Brentuximab Vedotin or Crizotinib and Combination Chemotherapy in Treating Patients With Newly Diagnosed Stage II-IV Anaplastic Large Cell Lymphoma
Phase 2 Completed
137 enrolled 13 charts
T Cells Expressing a Fully-Human Anti-CD30 Chimeric Antigen Receptor for Treating CD30-Expressing Lymphomas
Phase 1 Completed
26 enrolled 19 charts
Phase 2 Study of AT13387 (Onalespib) in ALK+ ALCL, MCL, and BCL-6+ DLBCL
Phase 2 Terminated
25 enrolled 15 charts
Interleukin-15 (IL-5) in Combination With Avelumab (Bavencio) in Relapsed/Refractory Mature T-cell Malignancies
Phase 1 Completed
8 enrolled 18 charts
Study of Akt Inhibitor MK2206 in Patients With Relapsed Lymphoma
Phase 2 Completed
60 enrolled 8 charts
Tipifarnib in Treating Patients With Relapsed or Refractory Lymphoma
Phase 2 Completed
93 enrolled 12 charts
Veliparib, Bendamustine Hydrochloride, and Rituximab in Treating Patients With Relapsed or Refractory Lymphoma, Multiple Myeloma, or Solid Tumors
Phase 1/2 Completed
43 enrolled 18 charts
Ifosfamide, Carboplatin, Etoposide, and SGN-30 in Treating Young Patients With Recurrent Anaplastic Large Cell Lymphoma
Phase 1/2 Terminated
5 enrolled 9 charts
UCN-01 (7-Hydroxystaurosporine) to Treat Relapsed T-Cell Lymphomas
Phase 2 Terminated
20 enrolled 13 charts
Flavopiridol in Treating Patients With Relapsed or Refractory Lymphoma or Multiple Myeloma
Phase 1/2 Terminated
46 enrolled 12 charts
Alisertib in Treating Patients With Relapsed or Refractory Peripheral T-Cell Non-Hodgkin Lymphoma
Phase 2 Completed
42 enrolled 10 charts
Sorafenib Tosylate in Treating Patients With Recurrent Aggressive Non-Hodgkin's Lymphoma
Phase 2 Completed
14 enrolled 7 charts
SGN-30 and Combination Chemotherapy in Treating Patients With Newly Diagnosed Anaplastic Large Cell Lymphoma
Phase 2 Terminated
6 enrolled 3 charts
17-AAG in Treating Patients With Relapsed or Refractory Anaplastic Large Cell Lymphoma, Mantle Cell Lymphoma, or Hodgkin's Lymphoma
Phase 2 Completed
22 enrolled 5 charts
Ixabepilone in Treating Patients With Relapsed or Refractory Aggressive Non-Hodgkin's Lymphoma
Phase 2 Completed
51 enrolled 14 charts